<DOC>
	<DOCNO>NCT00538005</DOCNO>
	<brief_summary>RATIONALE : Sorafenib may stop growth tumor cell block enzymes need cell growth . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth malignant melanoma block blood flow tumor . Drugs use chemotherapy , oxaliplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving sorafenib together bevacizumab oxaliplatin may kill tumor cell . PURPOSE : This phase I/II trial study side-effects best dose sorafenib give together bevacizumab oxaliplatin see well work treat patient metastatic malignant melanoma .</brief_summary>
	<brief_title>Sorafenib , Bevacizumab , Oxaliplatin Treating Patients With Metastatic Malignant Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - To determine maximum tolerate dose sorafenib tosylate administer bevacizumab oxaliplatin . - To determine effect treatment regimen complete partial response rate patient metastatic melanoma . - To determine effect treatment regimen progression-free overall survival patient metastatic melanoma . OUTLINE : This phase I dose-escalation study sorafenib tosylate follow phase II study . - Phase I : Patients receive bevacizumab IV 30-90 minute oxaliplatin IV 2 hour day 1 . Patients also receive oral sorafenib tosylate twice daily day 1-14 . Treatment repeat every 2 week absence disease progression unacceptable toxicity . - Phase II : Patients receive sorafenib tosylate maximum tolerate dose bevacizumab oxaliplatin phase I . After completion study therapy , patient follow least 5 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm melanoma Metastatic disease Measurable evaluable nonCNS disease Measurable disease , define unidimensionally measurable lesion determine physical exam , xray , CT scan , MRI , radiographic procedure Evaluable disease , define lesion see radiographically unidimensionally measurable Previously irradiate lesion document progression allow provide site metastatic disease No active brain metastasis Previously treat , respond brain metastasis allow , provide measurable disease outside CNS At least 3 week since prior chemotherapy 6 week since prior radiotherapy CNS disease PATIENT CHARACTERISTICS : Inclusion criterion : ECOG performance status 02 Life expectancy ≥ 3 month ANC ≥ 1,200/mm^3 Platelet count ≥ 100,000/mm^3 Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 50 mL/min Bilirubin ≤ 3.0 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception EKG evidence serious arrhythmia recent myocardial infarction Exclusion criterion : Active infection Chronic underlie immunodeficiency disease Other serious concurrent illness Other form cancer within 5 year initial diagnosis except nonmelanoma skin cancer cervical cancer Congestive heart failure myocardial infarction within past 6 month PRIOR CONCURRENT THERAPY : Inclusion criterion : See Disease Characteristics At least 6 week since prior radiotherapy More 4 week since prior surgery Prior biologic therapy allow Exclusion criterion : Prior cytotoxic agent Prior sorafenib tosylate , bevacizumab , oxaliplatin Concurrent biological therapy , except growth factor anemia , neutropenia , thrombocytopenia Concurrent radiotherapy , chemotherapy , surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
</DOC>